Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Even if human research and clinical practice find a way to integrate personal health data, uptake will remain limited unless people are incentivized to participate.
Digital medicine companies can incorporate and build on existing business models in tech and biomedicine to bring transformational new products to market and eventually reshape medicine.
For the benefits of digital medicine to be fully realized, we need not only to find a shared home for personal health data but also to give individuals the right to own them.
The courts' new approach not only puts the US biotech industry at a competitive disadvantage but also misapprehends the nature of innovation in biotech.
Mauro Ferrari and colleagues discuss the biological barriers to delivery of nanoparticle therapeutics to diseased tissues. They propose that greater emphasis should be place on rational particle design that systematically takes into account these barriers.
An advocacy group provides a unique opportunity for professional development that is making a difference for women in scientific and technical careers.
